Cannapharmarx, INC 8-K filings

CannaPharmaRX, Inc. announced its 2026 growth strategy focusing on European expansion and new cannabis strains, alongside a director's resignation and the revocation of a cease trade order.

CannaPharmaRX, Inc. announced the revocation of its cease trade order but disclosed significant financial challenges including a going concern doubt and substantial debt.

CannaPharmaRX, Inc. has entered into payment schedules with two major debtholders to manage outstanding debts and avoid further defaults, while retaining capital for operations.

CannaPharmaRX announces successful shipments to Israel and Germany, highlighting strong demand and expansion plans.

CannaPharmaRX appoints Constantine Nkafu as interim CEO and adds Constantine Nkafu and Elliot Zemel to its Board of Directors.

CannaPharmaRX, Inc. has engaged Barzily & Co. as its new independent registered public accounting firm, effective November 29, 2024.

CannaPharmaRX, Inc. has announced the resignation of its auditor, GreenGrowth CPAs, effective November 14, 2024, and is currently seeking a new auditor.

CannaPharmaRX, Inc. announces the resignation of its Chief Executive Officer, Dean Medwid, for personal reasons, with the Board of Directors commencing a search for a replacement.

CannaPharmaRX has finalized a supply agreement with Cantek, a leading Israeli medical cannabis distributor, for a minimum of 1,000 kg of cannabis annually.

CannaPharmaRX has entered into a three-year supply agreement with Cantek, an Israeli medical cannabis distributor, for a minimum of 1,000 kg of cannabis product annually.